Summary & Overview
HCPCS J7315: Mitomycin, Ophthalmic, 0.2 mg
HCPCS Level II code J7315 designates mitomycin ophthalmic 0.2 mg, a topical or intraoperative antimetabolite used in ophthalmology to limit scarring and improve surgical outcomes. This code identifies the drug product itself for billing and coverage decisions and is relevant across ambulatory surgical centers, hospital outpatient departments, and specialty ophthalmology settings nationwide. Its use affects procedure-related drug charges, payer coverage determinations, and facility billing workflows.
Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of payer coverage patterns, common billing and coding considerations, and the clinical context in which mitomycin ophthalmic is used. The publication summarizes benchmarks for utilization and reimbursement where available, highlights policy updates affecting HCPCS drug coding and billing, and outlines implications for billing teams and ophthalmology practices.
The report does not provide clinical recommendations. It focuses on coding accuracy, documentation implications for billing mitomycin ophthalmic products, and the administrative considerations providers and billing staff should track when using HCPCS Level II code J7315 in practice.
Billing Code Overview
HCPCS Level II code J7315 represents Mitomycin, ophthalmic, 0.2 mg administered for ophthalmic indications. The service is an ophthalmic medication administration used during or in conjunction with eye procedures to inhibit fibroblast proliferation and reduce postoperative scarring.
-
Service type: Ophthalmic therapeutic agent
-
Typical site of service: Ambulatory surgical centers, hospital outpatient departments, and specialty ophthalmology clinics where intraoperative or office-based ocular procedures are performed
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 68-year-old patient with recurrent pterygium and conjunctival scarring presents to an outpatient ophthalmology surgical suite for excision of the pterygium with intraoperative adjunctive therapy. The ophthalmic surgeon prepares compounded Mitomycin ophthalmic solution dosed as 0.2 mg (HCPCS Level II code J7315) to apply topically to the scleral bed following lesion excision to reduce fibrovascular regrowth. Typical workflow: preoperative evaluation in clinic documents indication and informed consent; verification of ocular laterality and medication allergies; surgical time-out in the procedure room; sterile preparation and local or monitored anesthesia care; pterygium excision; application of Mitomycin, ophthalmic, 0.2 mg with timed exposure on soaked sponges and subsequent irrigation; optional conjunctival autograft or amniotic membrane placement; postoperative instructions and topical antibiotic/anti-inflammatory prescriptions; follow-up visits to monitor healing and detect complications such as delayed epithelialization or scleral thinning. Typical site of service is an ambulatory surgical center or hospital outpatient department; minor office-based procedures for topical application may occur when facility policies and state regulations permit.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|